Policy | August 11, 2021
NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Nearly 6,000 patients have been treated with the drug since 2017
Company working on COVID vaccine INO 4800
A veteran in cell therapy and oncology commercialisation
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
